SecBot SecBot
SECBOTREPLAY Home › Report › PTCT

PTCT · PTC Therapeutics is holding its 2026 annual meeting to elect four Class…

PTC THERAPEUTICS, INC. · DEFA14A filed Apr 20, 2026 at 16:31 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Apr 20, 2026 at 16:31 ET

PTC Therapeutics is holding its 2026 annual meeting to elect four Class I directors, including Jessica Chutter who was recently appointed to the board. This filing is a definitive proxy statement soliciting shareholder votes on director elections, auditor ratification, and executive compensation. The filing follows a recent 8-K filing announcing Chutter's appointment and other board/executive changes, suggesting these materials are part of an ongoing governance process.

  • PTC Therapeutics is holding its 2026 annual meeting to elect four Class I directors: Jessica Chutter, Matthew B. Klein, Stephanie S. Okey, and Jerome B. Zeldis
  • The proxy statement solicits votes on three proposals: election of directors, ratification of Ernst & Young as auditors, and approval of executive compensation
  • This filing follows a March 25, 2026 Form 8-K announcing Jessica Chutter's appointment to the board and other executive changes
  • The filing is routine corporate governance documentation for the annual shareholder meeting

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access